|1.||Hamel, Ernest: 7 articles (05/2015 - 06/2005)|
|2.||Li, Wei: 2 articles (06/2015 - 11/2012)|
|3.||Miller, Duane D: 2 articles (06/2015 - 11/2012)|
|4.||Bai, Ruoli: 2 articles (09/2014 - 01/2013)|
|5.||Brancale, Andrea: 2 articles (01/2013 - 06/2012)|
|6.||Day, Bryan W: 1 article (12/2015)|
|7.||Phoa, Athena F: 1 article (12/2015)|
|8.||Wong, Chin: 1 article (12/2015)|
|9.||Stringer, Brett W: 1 article (12/2015)|
|10.||Browne, Stephen: 1 article (12/2015)|
06/24/2015 - "A series of 1-benzene acyl-2-(1-methylindol-3-yl)-benzimidazole derivatives were designed, synthesized and evaluated as potential tubulin polymerization inhibitors and for the cytotoxicity against anthropic cancer cell lines. "
01/10/2013 - "Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors."
06/14/2012 - "A new series of tubulin polymerization inhibitors based on the 2-aryl/heteroaryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazole scaffold was synthesized and evaluated for growth inhibition activity on a panel of cancer cell lines, cell cycle effects, and in vivo potency. "
01/01/2011 - "Modifications on the CA-4 structure have led to a great number of novel CA-4 derivatives as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer. "
11/01/2003 - "Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment."
|2.||Breast Neoplasms (Breast Cancer)
06/09/1995 - "The tubulin polymerization inhibitors in this series displayed significantly higher cytotoxicities in the MDA-MB-435 breast cancer cell line than in the other cell lines studied. "
07/01/2009 - "Three-dimensional (3D) quantitative structure-activity relationship (QSAR) and docking studies of 43 tubulin inhibitors, 2-phenylindole derivatives with anticancer activity against human breast cancer cell line MDA-MB 231, have been carried out. "
07/01/1993 - "Currently, some of fluoropyrimidine compounds, methotrexate analogues, tubulin inhibitors from plant origins have shown their clinical activities against human non-small cell lung cancer and/or breast cancer. "
05/01/2006 - "Its growth-inhibitory effect was less affected by overexpression of P-glycoprotein than that of other tubulin inhibitors and was not affected by the overexpression of breast cancer resistance protein or multidrug resistance-associated protein. "
01/01/1998 - "Drug sensitivity was studied for the tubulin inhibitors taxol, taxotere, rhizoxin and for doxorubucin and cisplatin, in human lung and breast cancer cell lines, including drug-selected cell lines, overexpressing the membrane transporter P-glycoprotein (Pgp) or the multidrug resistance protein (MRP). "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2015 - "Several approaches are being investigated to overcome resistance in prostate cancer, including the use of novel taxanes and tubulin inhibitors, and the inhibition of cell survival pathways. "
03/01/2009 - "The data suggested that VEGF shRNA could significantly enhance the sensitivity of human prostate cancer to tubulin inhibitors."
03/01/2009 - "In this study, the antitumor activities of VEGF shRNA and tubulin inhibitors on human prostate cancer DU145 cells was investigated, and shRNA transient expression plasmid pCSH1-VEGF targeting VEGF mRNA was constructed. "
09/15/2014 - "Biological activity profile studies (COMPARE analysis) demonstrated that 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides act as tubulin inhibitors, and this conclusion was confirmed via biochemical assays with pure tubulin and demonstration of increased numbers of mitotic cells following treatment of a leukemia cell line."
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Small Interfering RNA (siRNA)
|4.||Messenger RNA (mRNA)
|8.||combretastatin A-4 (combretastatin A4)
|9.||flavone acetic acid
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)